ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag big pharma disease medicine developmental biology

Microfluidics: Biology’s Liquid Revolution
Laura Tran, PhD | Feb 26, 2024 | 8 min read
Microfluidic systems redefined biology by providing platforms that handle small fluid volumes, catalyzing advancements in cellular and molecular studies.
Two sets of identical twin children sitting
Identical Twins Carry Distinctive Epigenetic Marks: Study
Chloe Tenn | Sep 30, 2021 | 2 min read
Researchers found more than 800 sites in the genome where the twins bore the same chemical tags.
Career Supplement | Big Makeover for Big Pharma
Alison McCook | Jun 19, 2005 | 10 min read
Since the New York City life science technology-consulting firm Intrasphere Technologies opened an office in India, Samuel Goldman, cofounder and chief technology officer, says he works fairly bizarre hours, scheduling 6:00 A.M. meetings on a "regular basis."
Cropped view of senior man playing with puzzles
A Rare Genetic Mutation Protects Against Alzheimer's Disease
Hannah Thomasy, PhD, Drug Discovery News | Sep 17, 2023 | 4 min read
Data from a highly resilient individual guided researchers to new potential therapeutic targets.
Woman smiling at the camera working out on a blue yoga mat.
Keeping Older Muscles Strong
Hannah Thomasy, PhD, Drug Discovery News | Sep 5, 2023 | 5 min read
From stem cell-recruiting gels to hormone cycle restoration, Tracy Criswell has big ideas about how to combat age-related decline in muscle regeneration.
Single Nucleotide Polymorphisms: Big Pharma Hedges its Bets
Eugene Russo | Jul 18, 1999 | 7 min read
SNP CENTRAL: A genetics researcher takes to the bench at the Wellcome Trust's Sanger Centre in Cambridge, England. The sequencing center and its London sponsor provided key leadership in the SNP Consortium, a public-private venture to find and map 300,000 single nucleotide polymorphisms. The Wellcome Trust helped entice 10 pharmaceutical firms to join the consortium by putting up $14 million of the project's estimated $45 million price tag. The Sanger Centre will provide much of the radiation h
Valerie Arboleda Uses Big Data to Unravel the Biology of a Rare Disease
Shawna Williams | May 1, 2018 | 3 min read
The UCLA geneticist examines how defects in a histone protein lead to symptoms throughout the body.
Make Mine Rare
Megan Scudellari | Aug 1, 2011 | 7 min read
With mounting interest from biotechs, Big Pharma, and the federal government, research on rare diseases is burgeoning.
Stem Cell Trial for Eye Disease Commences
Jef Akst | Sep 12, 2014 | 2 min read
Researchers at the RIKEN Center for Developmental Biology will treat the first patient in its clinical trial testing an induced pluripotent stem cell-based treatment for age-related macular degeneration.
The Scientist at Work in Big Pharma
Robert Calandra | Jan 26, 2003 | 5 min read
Ensconced in a darkened room at GlaxoSmithKline's suburban Philadelphia campus, Lara Kallander brings up an image of an X-ray crystallized compound on a wall screen. The image looks like a heap of brightly colored children's pickup-sticks arrayed at random angles. Kallander puts on a weighty pair of 3-D glasses. At first the left eye is annoyingly fuzzy, as if the lens is smudged. Then she hits a few keystrokes on the computer and suddenly the pickup sticks seem to pop off the screen. The lin

Run a Search

ADVERTISEMENT